Related references
Note: Only part of the references are listed.Treatment Rationale and Design for J-SONIC: A Randomized Study of Carboplatin Plus Nab-paclitaxel With or Without Nintedanib for Advanced Non-Small-cell Lung Cancer With Idiopathic Pulmonary Fibrosis
Kohei Otsubo et al.
CLINICAL LUNG CANCER (2018)
Diagnosis of Idiopathic Pulmonary Fibrosis An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Ganesh Raghu et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
Pemetrexed-related interstitial lung disease reported from post marketing surveillance (malignant pleural mesothelioma/non-small cell lung cancer)
Keisuke Tomii et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2017)
Antifibrotic role of vascular endothelial growth factor in pulmonary fibrosis
Lynne A. Murray et al.
JCI INSIGHT (2017)
Differential Expression of VEGF-Axxx Isoforms Is Critical for Development of Pulmonary Fibrosis
Shaney L. Barratt et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2017)
A proteomics approach to identifying key protein targets involved in VEGF inhibitor mediated attenuation of bleomycin-induced pulmonary fibrosis
Yogesh M. Kulkarni et al.
PROTEOMICS (2016)
The Efficacy and Safety of Chemotherapy in Patients With Nonsmall Cell Lung Cancer and Interstitial Lung Disease A PRISMA-Compliant Bayesian Meta-Analysis and Systematic Review
Yu Jie Chen et al.
MEDICINE (2015)
Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease
Motoyasu Kato et al.
BMC CANCER (2014)
The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung disease
Ryoko Shimizu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease
Moon Ki Choi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Non-Small Cell Lung Cancer, Version 1.2015
David S. Ettinger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2014)
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Luca Richeldi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Vascular Endothelial Growth Factor in Acute Lung Injury and Acute Respiratory Distress Syndrome
S. Barratt et al.
RESPIRATION (2014)
Reference values for spirometry, including vital capacity, in Japanese adults calculated with the LMS method and compared with previous values
Masaru Kubota et al.
RESPIRATORY INVESTIGATION (2014)
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
William D. Travis et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2013)
Diagnosis and Treatment of Connective Tissue Disease-Associated Interstitial Lung Disease
Rekha Vij et al.
CHEST (2013)
Association between cytokine removal by polymyxin B hemoperfusion and improved pulmonary oxygenation in patients with acute exacerbation of idiopathic pulmonary fibrosis
Keiji Oishi et al.
CYTOKINE (2013)
Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Katerina M. Antoniou et al.
RESPIRATION (2013)
Efficacy of Chemotherapy for Advanced Non-Small Cell Lung Cancer with Idiopathic Pulmonary Fibrosis
Naohiro Watanabe et al.
RESPIRATION (2013)
Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer
Seiji Niho et al.
LUNG CANCER (2012)
Lung Cancer and Interstitial Lung Diseases: A Systematic Review
Kostas Archontogeorgis et al.
PULMONARY MEDICINE (2012)
The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias
Yuji Minegishi et al.
LUNG CANCER (2011)
MMP expression and abnormal lung permeability are important determinants of outcome in IPF
S. McKeown et al.
EUROPEAN RESPIRATORY JOURNAL (2009)
VEGFR-2 antagonist SU5416 attenuates bleomycin-induced pulmonary fibrosis in mice
Xue-Mei Ou et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2009)
Basis of acute exacerbation of idiopathic pulmonary fibrosis in Japanese patients
Arata Azuma et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2008)
Interstitial lung disease in Japanese patients with lung cancer - A cohort and nested case-control study
Shoji Kudoh et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2008)
Acute exacerbations of idiopathic pulmonary fibrosis
Harold R. Collard et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
The early responses of VEGF and its receptors during acute lung injury: implication of VEGF in alveolar epithelial cell survival
Marco Mura et al.
CRITICAL CARE (2006)
Pathophysiological consequences of VEGF-induced vascular permeability
SM Weis et al.
NATURE (2005)
Standardisation of the measurement of lung volumes
J Wanger et al.
EUROPEAN RESPIRATORY JOURNAL (2005)
Anti-vascular endothelial growth factor gene therapy attenuates lung injury and fibrosis in mice
N Hamada et al.
JOURNAL OF IMMUNOLOGY (2005)
The epidemiology of interstitial lung disease and its association with lung cancer
G Raghu et al.
BRITISH JOURNAL OF CANCER (2004)
Angiogenic cytokines in patients with idiopathic interstitial pneumonia
NR Simler et al.
THORAX (2004)
Vascular endothelial growth factor may contribute to increased vascular permeability in acute respiratory distress syndrome
DR Thickett et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2001)
Vascular endothelial growth factor synthesis in the acute phase of experimental and clinical lung injury
B Maitre et al.
EUROPEAN RESPIRATORY JOURNAL (2001)
Share Paper
